The Government has taken various regulatory measures since 2019 to ensure the quality of medicines in the country. The key measures are as under:
The Drugs Rules, 1945 were amended providing that every Active Pharmaceutical Ingredient (bulk drug) manufactured or imported in India shall bear Quick Response Code on its label. The stored data or information shall include the minimum particulars including Unique product identification code, Batch No, Manufacturing date, Expiry Date.
The Drugs Rules, 1945 were amended providing that any marketer who sells or distributes any drug shall be responsible for quality of that drug as well as other regulatory compliances along with the manufacturer under these rules.
The Drugs Rules, 1945 were amended providing that “in case the applicant intends to market the drug under a brand name or trade name, the applicant shall furnish an undertaking in Form 51 to the Licensing Authority to the effect that to the best of his knowledge based on search in trademarks registry, central data base for brand name or trade name of drugs maintained by Central Drugs Standard Control Organisation, literature and reference books on details of drug formulations in India, and internet, such or similar brand name or trade name is not already in existence with respect to any drug in the country and the proposed brand name or trade name shall not lead to any confusion or deception in the market”.
The manufacture for sale, sale and distribution of 80 Fixed Dose Combinations (FDCs) drugs in India were prohibited in public interest after consultation with the Drugs Technical Advisory Board.
220 additional posts of various levels have been created including Joint Drugs Controller, Deputy Drugs Controller, Asst. Drugs Controller and Drugs Inspector in the year 2022-23.
Further, Department of Pharmaceuticals has launched a scheme, namely, Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP). Under the scheme, Generic Medicines are sold through dedicated outlets namely Pradhan Mantri Bhartiya Janaushadhi Kendras (PMBJKs). It is an initiative of Government of India towards making an impact on common masses to provide quality medicines at affordable prices. As on 30.06.2022, 8,742 Janaushadhi Kendras have been opened across the country and the product basket of PMBJP comprises 1,616 drugs and 250 surgical items.
The Union Minister of State for Health and Family Welfare, Dr. Bharati Pravin Pawar stated this in a written reply in the Rajya Sabha today.
Bulletin
Government has taken various regulatory measures since 2019 to ensure the quality of medicinal products in country
More from this track
Related reading
Bulletin
Union Ministry of Health and Family Welfare Hosts High-Level Panel Discussion on “Scaling AI for Public Health Impact: Public-Private Partnership” at India AI Impact Summit 2026
Union Ministry of Health and Family Welfare today hosted a high-level panel discussion on the theme “Scaling AI...
Feb
Bulletin
Chintan Shivir in Ahmedabad focuses on scaling pharma exports as India crosses $30 billion mark
An Industry Interaction on the theme “Scaling up Pharma Exports” was held under the Chintan Shivir series being...
Feb
Bulletin
Union Minister of Commerce and Industry Shri Piyush Goyal Calls for Ambitious India-Brazil Trade Surge Beyond USD 15 Billion, Deeper Ties in Defence, Renewables, Pharma and Emerging Tech
Union Minister of Commerce and Industry Shri Piyush Goyal addressed the Plenary Session of the India–Brazil Business Forum...